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1. INTRODUCTION {#cam42753-sec-0005}
===============

Intracranial ependymomas (EPNs) constitute the second most prevalent malignant brain tumor in children, while only account for approximately 3%‐5% of central nervous system (CNS) tumors in adult.[1](#cam42753-bib-0001){ref-type="ref"}, [2](#cam42753-bib-0002){ref-type="ref"}, [3](#cam42753-bib-0003){ref-type="ref"} These tumors are thought to arise from ependymal cells lining the cerebral ventricles, spinal cord central canal, and cortical rests.[4](#cam42753-bib-0004){ref-type="ref"}, [5](#cam42753-bib-0005){ref-type="ref"} According to the World Health Organization (WHO) classification system,[6](#cam42753-bib-0006){ref-type="ref"} EPNs have traditionally been divided into 3 grades, grade I subependymomas and myxopapillary, grade II classic EPNs and grade III as anaplastic type. Clinical management of intracranial grade II/III EPN is usually challenging for its locally invasive growth pattern.[7](#cam42753-bib-0007){ref-type="ref"} For substantial heterogeneity in the natural course and prognosis of this disease, estimating survival is always difficult, even for experienced neurosurgeon. Recognizing the importance of survival prediction for assisting in clinical decision making and optimization of therapeutic approaches in clinical care, a precise prognostic tool tailored to individual patient factors is need for these patients.

At present, WHO grading is employed to stratify the EPNs from throughout the CNS for predicting survival outcomes.[7](#cam42753-bib-0007){ref-type="ref"} However, this WHO grade‐based risk classification is considered contentious and inconclusive for its limited predictive power without good consistent associations with patient prognosis.[7](#cam42753-bib-0007){ref-type="ref"}, [8](#cam42753-bib-0008){ref-type="ref"}, [9](#cam42753-bib-0009){ref-type="ref"}, [10](#cam42753-bib-0010){ref-type="ref"} To date, there is no reliable statistical prediction model designed to conduct individualized estimation of survival for patients with intracranial EPN.

In addition, despite the age‐ and site‐specific prognostic factors among these tumors, for its rarity, some studies grouped all ages and occurrence sites together for survival analysis, making the differences among subsets unclear. Thus, in this study, we sought to conduct comprehensive prognostic evaluations focusing on the primary intracranial grade II/III EPNs in children and adults, and develop nomograms for reliable estimation of 3‐, 5‐, and 8‐year survival.

2. METHODS {#cam42753-sec-0006}
==========

2.1. Study population {#cam42753-sec-0007}
---------------------

The data of study population were extracted from the National Cancer Institute\'s Surveillance, Epidemiology, and End Results (SEER) database in the United States. The SEER program is a population‐based cancer registry system capturing data on patient demographics, clinicopathologic features, and cancer‐associated treatment, covering nearly 30% of the US population.[11](#cam42753-bib-0011){ref-type="ref"} The inclusion criteria were as follows: (a) diagnosed with malignant EPN as defined by the International Classification of Diseases for Oncology Third Edition (ICD‐O‐3) histology codes 9391/3, 9392/3 and 9393/3 (ependymoma, anaplastic ependymoma, and papillary ependymoma); (b) diagnosed from 1988 to 2015; (c) primary tumor location labeled C71.0‐C71.9 according to ICD‐O‐3 site; (d) EPN was the only or the first malignancy; (e) patients had complete follow‐ups. And patients with unknown race, tumor extension, tumor size, surgery type, and radiotherapy were excluded.

2.2. Study variables and endpoints {#cam42753-sec-0008}
----------------------------------

Following variables were extracted from the SEER database including age at diagnosis, race (white or non‐white), sex (male or female), histological type (grade II: classic EPN; grade III: anaplastic EPN), tumor location (supratentorial, infratentorial, or others), tumor size, tumor extension, surgery treatment, radiotherapy (yes or no), chemotherapy (yes or no), and marital status (married, single or unknown). For pediatric patients (\<18 years), the age was divided into three groups, ≤2 years, 3‐7 years, and 8‐17 years, based on the best cut‐off points determined by X‐tile program (Figure [S1](#cam42753-sup-0001){ref-type="supplementary-material"}A‐C). Similarly, the age of adult patients (\>18 years) was grouped as 18‐53 years, 54‐68 years, and \>68 years (Figure [S1](#cam42753-sup-0001){ref-type="supplementary-material"}D‐F). Tumor size was grouped by median value in both pediatric and adult cohorts. Tumor extension was divided into localized, regional and distant, in accordance with our previous report.[12](#cam42753-bib-0012){ref-type="ref"} According to SEER site‐specific coding guidelines, the extent of surgical resection was categorized as no surgery, biopsy/subtotal resection (STR), and gross total resection (GTR). Overall survival (OS) was defined as the primary outcome.

2.3. Nomogram development and statistical analyses {#cam42753-sec-0009}
--------------------------------------------------

In both pediatric and adult cohorts, patients were randomly divided into training and validation sets at a ratio of 7:3. Univariate and multivariate Cox proportional hazards regression analyses were conducted to identify prognostic factors (*P* \< .05) that significantly associated with OS in the training groups. Ground on the results of multivariate Cox analyses, nomograms were established to estimate 3‐, 5‐, and 8‐year OS rates for EPN patients. Then, the nomogram models were internally validated. Discrimination ability of the nomograms were evaluated by concordance index (C‐index), and time‐dependent receiver operating characteristic curve (ROC) with the area under the curve (AUC) value. Calibration curve was applied to access the consistency between nomogram predicted OS and actual outcome. Bootstrap resampling (1000 resamples) were conducted for these analyses. Additionally, the clinical usefulness of the nomogram models was accessed by decision curve analysis (DCA).

In addition, we calculated the scores for each patient in the training cohorts using the nomogram models. Then, according to the total score of each patient, risk classification systems were established to assign patients into a high‐, intermediate‐, or low‐risk group by best cut‐off values. And Kaplan‐Meier curve and the log‐rank test were employed to illustrate and compare the OS of patients in the different risk groups.

The X‐tile program (version 3.6.1) was applied to determine the best cut‐off points. Survival curves were depicted using Kaplan‐Meier method. Comparisons across age categories and random groups used Chi‐square tests or Student *t* tests, as appropriate. The SEER\*Stat software (version 8.3.5), SPSS software (version 24.0) and R software (version 3.13) were used for all statistical analyses. *P* value \<.05 was considered statistically significant.

3. RESULTS {#cam42753-sec-0010}
==========

3.1. Patient characteristics {#cam42753-sec-0011}
----------------------------

Owing to known differences in multiple characteristics between pediatric and adult patients with EPN, 1390 eligible patients were divided by age (667 children; 723 adults) for all analyses (Table [1](#cam42753-tbl-0001){ref-type="table"}). Overall, more than half (52.9%) of the patients were male, and white (80.4%) accounted for the vast majority population. Based on comparative analyses, pediatric and adult patients were fairly well balanced regarding to sex and race; however, statistically significant differences were found between two groups for tumor grade distribution, tumor site, tumor extension, tumor size and treatment options. Grade III EPN (42.9% vs 22.5%) and tumor with larger size (50.95 vs 37.69 mm) were more common observed in children, and these patients were more likely to receive GTR (60.6% vs 45.1%), radiotherapy (70.0% vs 58.4%) or chemotherapy (36.7% vs 5.9%) than adult patients. In addition, the baseline characteristics were comparable between the training and validation cohorts in both pediatric and adult cohorts, as summarized in Table [2](#cam42753-tbl-0002){ref-type="table"}.

###### 

Patient characteristics in the study

  Variable          Category         All            Pediatric     Adult         *P* [a](#cam42753-note-0004){ref-type="fn"}
  ----------------- ---------------- -------------- ------------- ------------- ---------------------------------------------
  Total                              1390 (100%)    667 (100%)    723 (100%)     
  Age               ≤2               238 (17.1%)    238 (35.7%)                  
                    3‐7              218 (15.7%)    218 (32.7%)                  
                    8‐17             211 (15.2%)    211 (31.6%)                  
                    18‐53            486 (35.0%)                  486 (67.2%)    
                    54‐68            160 (11.5%)                  160 (22.1%)    
                    \>68             77 (5.5%)                    77 (10.7%)     
  Sex               Female           654 (47.1%)    307 (46.0%)   347 (48.0%)   .463
                    Male             736 (52.9%)    360 (54.0%)   376 (52.0%)    
  Race              White            1117 (80.4%)   528 (79.2%)   589 (81.5%)   .280
                    Non‐white        273 (19.6%)    139 (20.8%)   134 (18.5%)    
  WHO grade         Grade II         941 (67.7%)    381 (57.1%)   560 (77.5%)   **\<.001**
                    Grade III        449 (32.3%)    286 (42.9%)   163 (22.5%)    
  Tumor site        Supratentorial   590 (42.4%)    245 (36.7%)   345 (47.7%)   **\<.001**
                    Infratentorial   543 (39.1%)    256 (38.4%)   287 (39.7%)    
                    Others           257 (18.5%)    166 (24.9%)   91 (12.6%)     
  Tumor extension   Localized        1131 (81.4%)   519 (77.8%)   612 (84.6%)   **.001**
                    Regional         236 (17.0%)    131 (19.6%)   105 (14.5%)    
                    Distant          23 (1.7%)      17 (2.5%)     6 (0.8%)       
  Tumor size        Mean (mm)        44.06          50.95         37.69         **\<.001**
                    Median (mm)      41             48            37             
  Surgery           No surgery       80 (5.8%)      17 (2.5%)     63 (8.7%)     **\<.001**
                    Biopsy/STR       580 (41.7%)    246 (36.9%)   334 (46.2%)    
                    GTR              730 (52.5%)    404 (60.6%)   326 (45.1%)    
  Radiotherapy      No               501 (36.0%)    200 (30.0%)   301 (41.6%)   **\<.001**
                    Yes              889 (64.0%)    467 (70.0%)   422 (58.4%)    
  Chemotherapy      No               1102 (79.3%)   422 (63.3%)   680 (94.1%)   **\<.001**
                    Yes              288 (20.7%)    245 (36.7%)   43 (5.9%)      
  Marital status    Single                                        301 (41.6%)    
                    Married                                       381 (52.7%)    
                    Unknown                                       41 (5.7%)      

The bold values represent statistical significance.

Abbreviations: GTR, gross total resection; STR, subtotal resection.

Chi square test or Student *t* test.
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###### 

Patient characteristics of the trainings and internal validations

  Variable          Category         Pediatric     Adult                                            
  ----------------- ---------------- ------------- ------------- ------ ------------- ------------- ------
  Total                              466 (100%)    201 (100%)           506 (100%)    217 (100%)     
  Age               ≤2               161 (34.5%)   77 (38.3%)    .635                                
                    3‐7              154 (33.0%)   64 (31.8%)                                        
                    8‐17             151 (32.4%)   60 (29.9%)                                        
                    18‐53                                               339 (67.0%)   147 (67.7%)   .777
                    54‐68                                               115 (22.7%)   45 (20.7%)     
                    \>68                                                52 (10.3%)    25 (11.5%)     
  Sex               Female           222 (47.6%)   85 (42.3%)    .203   246 (48.6%)   101 (46.5%)   .609
                    Male             244 (52.4%)   116 (57.7%)          260 (51.4%)   116 (53.5%)    
  Race              White            362 (77.7%)   166 (82.6%)   .152   414 (81.8%)   175 (80.6%)   .710
                    Non‐white        104 (22.3%)   35 (17.5%)           55 (18.2%)    42 (19.3%)     
  WHO grade         Grade II         264 (56.7%)   117 (58.2%)   .709   392 (77.5%)   168 (77.4%)   .988
                    Grade III        202 (43.3%)   84 (41.8%)           114 (22.5%)   49 (22.6%)     
  Tumor site        Supratentorial   174 (37.3%)   71 (35.3%)    .701   241 (47.6%)   104 (47.9%)   .700
                    Infratentorial   174 (37.3%)   82 (40.8%)           198 (39.1%)   89 (41.0%)     
                    Others           118 (25.3%)   48 (23.9%)           67 (13.2%)    24 (11.1%)     
  Tumor extension   Localized        367 (78.8%)   152 (75.6%)   .630   425 (84.0%)   187 (86.2%)   .623
                    Regional         87 (18.7%)    44 (21.9%)           76 (15.0%)    29 (13.4%)     
                    Distant          12 (2.6%)     5 (2.5%)             5 (1.0%)      1 (0.5%)       
  Tumor size(mm)    \<48             241 (51.7%)   95 (47.3%)    .291                                
                    ≥48              225 (48.3%)   106 (52.7%)                                       
                    \<37                                                260 (51.4%)   101 (46.5%)   .233
                    ≥37                                                 246 (48.6%)   116 (53.5%)    
  Surgery           No surgery       14 (3.0%)     3 (1.5%)      .524   48 (9.5%)     15 (6.9%)     .411
                    Biopsy/STR       171 (36.7%)   75 (37.3%)           236 (46.6%)   98 (45.2%)     
                    GTR              281 (60.3%)   123 (61.2%)          222 (43.9%)   104 (47.9%)    
  Radiotherapy      No               140 (30.0%)   60 (29.9%)    .960   207 (40.9%)   94 (43.3%)    .547
                    Yes              326 (70.0%)   141 (70.1%)          299 (59.1%)   123 (56.7%)    
  Chemotherapy      No               298 (63.9%)   124 (61.7%)   .579   480 (94.9%)   200 (92.2%)   .160
                    Yes              168 (36.1%)   77 (38.3%)           26 (5.1%)     17 (7.8%)      
  Marital status    Single                                              204 (40.3%)   97 (44.7%)    .268
                    Married                                             276 (54.5%)   105 (48.4%)    
                    Unknown                                             26 (5.1%)     15 (6.9%)      

Abbreviations: GTR, gross total resection; STR, subtotal resection.

Chi square test or Student *t* test.

John Wiley & Sons, Ltd

3.2. Independent prognostic predictors for pediatric and adult patients {#cam42753-sec-0012}
-----------------------------------------------------------------------

In both pediatric and adult training cohorts, age, tumor grade, surgery treatment, and chemotherapy were significantly associated with OS using univariate Cox analyses (*P* \< .05, Table [3](#cam42753-tbl-0003){ref-type="table"}). Radiation treatment was significantly associated with OS in children whereas tumor site and size were significantly associated with outcomes in adult. After controlling for confounding variables by multivariate Cox analyses, ultimately, age, sex, tumor grade, surgery treatment, and radiotherapy were identified as independent predictors of OS for pediatric patients, and age, tumor grade, tumor size, surgery treatment, and marital status for adult patients (Figure [1](#cam42753-fig-0001){ref-type="fig"}).

###### 

Univariate Cox analyses in the training cohorts

  Variable          Category                   *P*          
  ----------------- -------------------------- ------------ ------------
  Age               3‐7 vs ≤2                  .211          
                    8‐17 vs ≤2                 **\<.001**    
                    8‐17 vs 3‐7                **.005**      
                    54‐68 vs 18‐53                          **.003**
                    \>68 vs 18‐53                           **\<.001**
                    \>68 vs 54‐68                           **\<.001**
  Sex               Male vs Female             .073         .132
  Race              Non‐white vs White         .745         .566
  WHO grade         Grade III vs Grade II      **.009**     **\<.001**
  Tumor site        Infra vs Supra             .111         **.026**
                    Others vs Supra            .183         .783
                    Others vs Infra            .910         .065
  Tumor extension   Regional vs Localized      .165         .398
                    Distant vs Localized       .070         .582
                    Distant vs Regional        .291         .756
  Tumor size(mm)    ≥48 vs \<48                .889          
                    ≥37 vs \<37                             **.016**
  Surgery           Biopsy/STR vs No surgery   .100         .165
                    GTR vs No surgery          **.004**     **\<.001**
                    GTR vs Biopsy/STR          **.006**     **\<.001**
  Radiotherapy      Yes vs No                  **.008**     .909
  Chemotherapy      Yes vs No                  **.001**     **.002**
  Marital status    Married vs Single                       .081

The bold values represent statistical significance.

Abbreviations: GTR, gross total resection; Infra, infratentorial; Supra, supratentorial; STR, subtotal resection.

John Wiley & Sons, Ltd

![Forest plots showing results of multivariate Cox analyses in the training cohorts. GTR, gross total resection; Infra, infratentorial; Supra, supratentorial; STR, subtotal resection](CAM4-9-615-g001){#cam42753-fig-0001}

3.3. Construction and validation of the age‐specific nomograms {#cam42753-sec-0013}
--------------------------------------------------------------

To individualize the 3‐, 5‐, and 8‐year predicted OS probability for pediatric and adult patients, nomograms were developed on basis of the results of multivariate Cox analyses, and were internally validated (Figure [2](#cam42753-fig-0002){ref-type="fig"}). The final age‐specific nomograms for children and adult showed favorable discrimination in the training cohorts (C‐index for pediatric, 0.67; C‐index for adult, 0.74), and the C‐index were similar in the validation cohorts (0.66 for pediatric and 0.74 for adult). With respect to calibration, excellent tracking of nomogram predictions vs observed outcomes was also observed (Figure [3](#cam42753-fig-0003){ref-type="fig"}).

![Nomograms estimating the probability of 3‐, 5‐ and 8‐year overall survival for pediatric (A) and adult (B) patients with intracranial grade II/III ependymoma. STR, subtotal resection; GTR, gross total resection](CAM4-9-615-g002){#cam42753-fig-0002}

![Calibration curves for predicting patient survival at each time point in the pediatric training set (A), pediatric validation set (B), adult training set (C), and adult validation set (D). Nomogram‐predicted survival is plotted on the x‐axis, and actual survival is plotted on the y‐axis. A plot along the 45‐degree line (dashed line) would indicate a perfect calibration model in which the predicted probabilities are identical to the actual outcomes](CAM4-9-615-g003){#cam42753-fig-0003}

We further compared the predictive accuracy between the nomogram models and different conventional clinical characteristics. Comparing the AUCs for ROC curves indicated that nomogram models had best discriminative ability in both pediatric and adult cohorts (Figure [4](#cam42753-fig-0004){ref-type="fig"}A‐F). And using time‐dependent C‐index, nomogram models outperformed all other single variables at different times after diagnosis (Figure [4](#cam42753-fig-0004){ref-type="fig"}G, H). Finally, DCA demonstrated that nomogram models exhibited the best net benefit for 3‐, 5‐, and 8‐year OS, indicating the favorable clinical utility of these predictive models (Figure [5](#cam42753-fig-0005){ref-type="fig"}). In sum, these findings suggested that the age‐specific nomograms had better performance in predicting short‐term or long‐term OS in malignant EPN patients than individual prognostic factors.

![The prognostic performances were compared between nomogram models and different conventional clinical characteristics by ROC curves and time‐dependent C‐index. Comparison of the ROC curves of the nomogram model and different conventional clinical characteristics for 3‐ (A), 5‐ (B) and 8‐y (C) OS prediction in the pediatric training set, and 3‐ (D), 5‐ (E) and 8‐y (F) OS prediction in the adult training set; The prognostic performance was compared between the nomogram model and different conventional clinical characteristics by calculating the C‐index in the pediatric (G) and adult (H) training sets. AUC, areas under the ROC curve; C‐index, concordance index; ROC, receiver operating characteristic curve](CAM4-9-615-g004){#cam42753-fig-0004}

![Decision curve analysis for the nomogram model and different conventional clinical characteristics in prediction of prognosis at 3‐y (A), 5‐y (B) and 8‐y (C) point in the pediatric training set, and at 3‐y (D), 5‐y (E) and 8‐y (F) point in the adult training set. The nomograms obtain more net benefits than all other single variables with a wider range of threshold probabilities](CAM4-9-615-g005){#cam42753-fig-0005}

3.4. Risk classification system {#cam42753-sec-0014}
-------------------------------

In addition to nomogram models, risk classification systems were constructed to assign patients into a high‐, intermediate‐ or low‐risk group according to the total score of each patient generated by the nomograms (Table [4](#cam42753-tbl-0004){ref-type="table"}). Based on the best cutoff values of corresponding cohorts obtained by X‐tile program, pediatric and adult patients were respectively divided into the low‐risk (score 0‐134 for pediatric and score 0‐90 for adult), intermediate‐risk (score 135‐166 for pediatric and 91‐129 for adult), and high‐risk groups (score ≥167 for pediatric and score ≥130 for adult). The Kaplan‐Meier curves revealed that prognosis of different risk groups could be accurately distinguished by the risk classification systems (Figure [6](#cam42753-fig-0006){ref-type="fig"}).

###### 

Score assignment and risk stratification

  Variable              Category            Score     
  --------------------- ------------------- --------- --------
  Age                   ≤2                  68         
                        3‐7                 58         
                        8‐17                0          
                        18‐53                         0
                        54‐68                         43
                        \>68                          100
  Sex                   Female              0          
                        Male                34         
  WHO grade             Grade II            0         0
                        Grade III           43        68
  Tumor size(mm)        \<37                          0
                        ≥37                           26
  Surgery               No surgery          100       41
                        Biopsy/STR          43        29
                        GTR                 0         0
  Radiotherapy          No                  32         
                        Yes                 0          
  Marital status        Single                        21
                        Married                       0
                        Unknown                       10
  Risk classification   Low‐risk            0‐134     0‐90
                        Intermediate‐risk   135‐166   91‐129
                        High‐risk           ≥167      ≥130

Abbreviations: GTR, gross total resection; STR, subtotal resection.

John Wiley & Sons, Ltd

![Kaplan‐Meier curves of overall survival for the low‐, intermediate‐, and high‐risk patients in the pediatric training set (A), pediatric validation set (B), adult training set (C) and adult validation set (D)](CAM4-9-615-g006){#cam42753-fig-0006}

4. DISCUSSION {#cam42753-sec-0015}
=============

A prognostic model with the ability to predict patient life expectancy is essential in personalizing therapy for tumor sufferers. As a statistical tool being widely applied in the field of cancer, the nomogram calculates all the cumulative effects of integrated key variables to estimate survival via an accessible, straightforward approach.[13](#cam42753-bib-0013){ref-type="ref"} The present study is, to our knowledge, the first study to develop nomograms for estimation of 3‐, 5‐, and 8‐year OS in EPNs, highlighting the relative contribution of easily accessible clinicopathologic variables to outcome prediction. We have demonstrated excellent discrimination and calibration of these predictive models in both training and validation cohorts. Besides, our nomogram models showed superiority in the clinical utility as well via DCA. Moreover, the novel proposed nomogram‐based risk classification systems could also help neurosurgeons to classify risk more objectively.

Our study highlighted the considerable heterogeneity in prognostic factors between children and adult with intracranial grade II/III EPN. For both pediatric and adult patients, age, tumor grade, and surgery treatment were independent predictors of OS, consistent with previous reports.[10](#cam42753-bib-0010){ref-type="ref"}, [14](#cam42753-bib-0014){ref-type="ref"} And we found surgical intervention was the strongest factor influencing the outcome in children, whereas age was the most influential one in adult. Male sex was significantly associated with poorer prognosis in children, while similar association was not found in adult. Based on a study combined all ages together for analysis, Rodríguez et al[14](#cam42753-bib-0014){ref-type="ref"} also found male sex was a significant predictor of worse survival. However, underlying differences between age groups were unrevealed in their research. Although the tendency of having discrete, pushing borders limits the study on the role of tumor size to some extent for such tumors,[15](#cam42753-bib-0015){ref-type="ref"} the effect of tumor space occupation cannot be ignored. In our investigation, larger tumor size was an independent risk factor for adult, but not for children. Furthermore, histology has also been found to have different prognostic significance depending on the tumor\'s anatomic location and the patient\'s age.[3](#cam42753-bib-0003){ref-type="ref"}, [16](#cam42753-bib-0016){ref-type="ref"} Raghunathan et al[3](#cam42753-bib-0003){ref-type="ref"} reported that the clinical relevance of specific histological features in EPN was associated with the anatomic site of origin. In our study, statistically significant differences between children and adults for tumor grade distribution was observed. These histopathological heterogeneities could also lead to differences in clinical behavior, response to therapy and patient outcomes. Future studies are needed to clarify the age‐specific significance of these histological features.

Significant correlations of marital status with cancer incidence, stage, treatment options, and prognosis have been determined,[17](#cam42753-bib-0017){ref-type="ref"}, [18](#cam42753-bib-0018){ref-type="ref"}, [19](#cam42753-bib-0019){ref-type="ref"} indicating the importance of social support for cancer detection, treatment, and survival. Consistently, we found that unmarried adult patients with EPN were at higher risk of worse outcomes for the first time.

Surgery and radiotherapy are the cornerstones of care for EPN in children.[10](#cam42753-bib-0010){ref-type="ref"}, [20](#cam42753-bib-0020){ref-type="ref"} GTR and adjuvant radiation significantly improved the survival of pediatric patients with intracranial grade II/III EPN in our study. For adult, surgery is regarded as the most crucial component of standard treatment,[10](#cam42753-bib-0010){ref-type="ref"}, [21](#cam42753-bib-0021){ref-type="ref"}, [22](#cam42753-bib-0022){ref-type="ref"} in agreement with our results. Remarkably, no clear correlation of radiation treatment with OS was observed. It was reported that radiation treatment should be applied for adult patients with grade III EPN and for adult patients with grade II EPN after STR.[10](#cam42753-bib-0010){ref-type="ref"}, [23](#cam42753-bib-0023){ref-type="ref"}, [24](#cam42753-bib-0024){ref-type="ref"} Grade II tumors taking up the majority in our study might mask the effect of radiotherapy. And these results also suggested that further evaluation on the role of radiotherapy is needed to determine the concrete application condition for adult patients. Furthermore, in spite of extensive investigation and research, the role of chemotherapy in the management of EPN remains unclear. Consistent with our results, several study cohorts of pediatric or adult patients in which the effect of chemotherapy was retrospectively analyzed also failed to demonstrate a survival advantage.[15](#cam42753-bib-0015){ref-type="ref"}, [25](#cam42753-bib-0025){ref-type="ref"}, [26](#cam42753-bib-0026){ref-type="ref"}, [27](#cam42753-bib-0027){ref-type="ref"} Nevertheless, this modality of treatment might be beneficial to some subsets of EPN patients with the ongoing therapeutic challenges.

Considering the difference between children and adult with EPN mentioned above, rather than simply adjusting for age, the age‐specific approach should be employed to estimate survival for these patients. Furthermore, with the development of tumor molecular biology, a number of immunohistochemical and genomic markers related to the prognosis have emerged, like chromosome 1q status, YAP1 fusion, RELA fusion and so on.[1](#cam42753-bib-0001){ref-type="ref"}, [2](#cam42753-bib-0002){ref-type="ref"}, [28](#cam42753-bib-0028){ref-type="ref"} Due to the limitation of SEER database without genomic data, we failed to incorporate additional variables to improve our models. But it is undeniable that, using easily measurable clinical parameters, our nomogram models are still in possession of favorable discrimination and clinical application value. Also, our study laid the foundation for the establishment of survival estimation model in intracranial EPNs.

Some other limitations should be acknowledged in our study. First, due to its retrospective nature, potentially generating selection bias is inevitable.[29](#cam42753-bib-0029){ref-type="ref"} Second, patients with missing information on the collected variables were excluded which could lead to a selection bias. Third, misclassification of histological type in EPN seems to be a problem even for EPN studies with central pathologic review.[30](#cam42753-bib-0030){ref-type="ref"}, [31](#cam42753-bib-0031){ref-type="ref"} Unable to re‐examine the tumor histology type could raise concern about the accuracy of the diagnosis in our investigation. Forth, SEER database does not include detail information of radiation treatment and chemotherapy. And information on recurrence status, clinical symptoms, comorbidities, and neurological status ware also unavailable. Finally, because our models only took the independent prognostic factors into consideration, survival rate of EPN patients would be underestimated by the nomogram models when it was low. Moreover, although models were established using large cohorts, external validations are still necessary.

5. CONCLUSION {#cam42753-sec-0016}
=============

Considerable heterogeneity in prognostic factors was highlighted between children and adult in our study. And we constructed and internally validated the first nomograms for accurate estimation of 3‐, 5‐, and 8‐year OS in patients with intracranial grade II/III EPN at an individualized level. The novel proposed nomogram‐based risk classification systems can be also used to facilitate risk stratification in EPNs for optimization of clinical management.
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